Liquidia Q2 net loss widens to $23.5M; YUTREPIA patent litigation advances, L606 license acquired

Liquidia Corp

2023-Q2 EPS reported -$0.54 revenue$9,279,000

Net loss $23.5M ($0.36/sh) vs $9.4M ($0.15/sh) in Q2 2022; revenue $4.8M, up from $3.9M.
CAFC affirmed '066 patent invalid/non-infringed; one patent ('793) on appeal to CAFC, briefing Q4 2023.
Filed amendment to add PH-ILD to YUTREPIA label; final approval gated by Tyvaso exclusivity ending March 31, 2024.
Licensed L606 from Pharmosa for $10M upfront; Phase 3 PH-ILD study planned in 2024 after FDA meeting.
Cash $88.2M as of June 30, 2023, vs $93.3M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Liquidia Corp reported second quarter ended June 30, 2023 results: revenue $4.8 million, net income $23.5 million, EPS $0.36 per basic and diluted share.

Period: second quarter ended June 30, 2023
Revenue: $4.8 million
Net income: $23.5 million
EPS: $0.36 per basic and diluted share
Result: reported results

Exact text from the filing

of PH-LD patients with L606. Second Quarter 2023 Financial Results Cash totaled $88.2 million as of June 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $4.8 million for the three months ended June 30, 2023, compared to $3.9 million for the three months ended June 30, 2022. Revenue related primarily to the promotion agreement between Liquidia

View on SEC.gov

Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-089437

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.